Ocugen Inc. is a biopharmaceutical company focused on developing gene therapies to cure blindness diseases and creating vaccines to combat infectious diseases. Primarily centered on advancing innovative clinical research, Ocugen is committed to addressing unmet medical needs in the ophthalmology sector, targeting debilitating eye conditions for which limited treatment options exist. Notably, Ocugen is also involved in the development and commercialization of a COVID-19 vaccine in partnership with Bharat Biotech, aiming to enhance global access to effective preventive measures. Headquartered in Malvern, Pennsylvania, Ocugen plays a significant role in the biotech industry through its contributions to both gene therapy and vaccine technologies. By progressing initiatives in vaccine distribution and novel therapeutic solutions, Ocugen positions itself as a vital entity within the healthcare market, striving to improve patient outcomes across diverse populations.